Impact of a waiver of intellectual property rights for COVID-19 therapeutics
![](https://www.ifpma.org/wp-content/uploads/2023/01/infographic_221205.jpg)
As WTO Member States continue to discuss an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics, latest evidence and data published today explains what the consequences of such a waiver would have on industry’s ability to fight the COVID-19 pandemic.
Any waiver will also have a significant adverse impact on the entire innovation ecosystem, that in turn will negatively affect industry’s ability to address future pandemics.